Camlin Fine Sciences Limited (BOM:532834)

India flag India · Delayed Price · Currency is INR
130.30
+8.90 (7.33%)
At close: May 27, 2026
Market Cap23.32B -19.6%
Revenue (ttm)17.52B +5.1%
Net Income276.27M
EPS1.46
Shares Out 192.09M
PE Ratio84.41
Forward PE25.03
Dividendn/a
Ex-Dividend Daten/a
Volume194,250
Open120.85
Previous Close121.40
Day's Range120.00 - 131.90
52-Week Range96.30 - 334.70
Beta0.72
AnalystsBuy
Price Target177.50 (+40.06%)
Earnings DateMay 26, 2026

About Camlin Fine Sciences

Camlin Fine Sciences Limited, together with its subsidiaries, research, develops, manufactures, and markets specialty chemicals, ingredients, and additive blend products in India and internationally. The company offers shelf-life solutions, which include basic ingredients, such as tert-butylhydroquinone (TBHQ), Butylated Hydroxyanisole (BHA), Butylated Hydroxytoluene (BHT), and Ascorbyl Palmitate (ASP); aroma ingredients, including vanillin and ethyl vanillin, natural vanillin, and some of its combinations; performance chemicals that include Hy... [Read more]

Industry Chemicals and Allied Products
Founded 1931
Employees 661
Stock Exchange Bombay Stock Exchange
Ticker Symbol 532834
Full Company Profile

Financial Performance

Financial Statements

News

Camlin Fine Sciences Transcript: Q4 25/26

Revenue and EBITDA were impacted by global logistics and raw material inflation, but strong growth in blends and vanillin, along with cost controls and discontinued loss-making operations, support a positive FY 2027 outlook with double-digit margins and robust order books.

1 day ago - Transcripts

Camlin Fine Sciences Quarterly report: Q4 2026

Camlin Fine Sciences has published its Q4 2026 quarterly earnings report on May 26, 2026.

1 day ago - Filings

Camlin Fine Sciences Slides: Q4 2026

Camlin Fine Sciences has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 26, 2026.

1 day ago - Filings

Camlin Fine Sciences Transcript: Q3 25/26

Q3 revenue grew 6% year-over-year to INR 572 crore, with blends up 11% and vanillin sales managed for future tariff benefits. Gross margin declined to 45%, but FY 2027 guidance targets 4,000 tons vanillin, 25% blends growth, and improved margins.

3 months ago - Transcripts

Camlin Fine Sciences Quarterly report: Q3 2026

Camlin Fine Sciences has published its Q3 2026 quarterly earnings report on February 13, 2026.

3 months ago - Filings

Camlin Fine Sciences Slides: Q3 2026

Camlin Fine Sciences has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on February 13, 2026.

3 months ago - Filings

Camlin Fine Sciences Transcript: Q2 25/26

Quarterly revenue grew 8.6% sequentially, with strong volume recovery and improved margins, despite ongoing tariff and realization pressures. Management reaffirmed full-year guidance and expects further growth from field force expansion and a new acquisition in France.

7 months ago - Transcripts

Camlin Fine Sciences Quarterly report: Q2 2026

Camlin Fine Sciences has published its Q2 2026 quarterly earnings report on November 10, 2025.

7 months ago - Filings

Camlin Fine Sciences Slides: Q2 2026

Camlin Fine Sciences has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on November 10, 2025.

7 months ago - Filings

Camlin Fine Sciences Transcript: Q1 25/26

Q1 FY2026 saw revenue and EBITDA decline due to plant shutdowns and one-time costs, but the blends business continued strong growth. Vanillin production ran at 50% capacity, with tariffs and channel inventory impacting near-term outlook. Gross margins are expected to stabilize at 40%-45%.

10 months ago - Transcripts

Camlin Fine Sciences Quarterly report: Q1 2026

Camlin Fine Sciences has published its Q1 2026 quarterly earnings report on August 8, 2025.

10 months ago - Filings

Camlin Fine Sciences Slides: Q1 2026

Camlin Fine Sciences has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on August 8, 2025.

10 months ago - Filings

Camlin Fine Sciences Q3 FY25 results: Revenue rises 8.7% YoY to Rs 435.5 crore, net loss at Rs 158.2 crore

The company attributed the net loss to several factors, including impairments on overseas subsidiaries, non-cash adjustments, and foreign exchange losses.

1 year ago - Business Upturn

Top stocks to buy today: Stock recommendations for February 7, 2025

Stock market recommendations: Bajaj Broking Research recommends buying Camlin Fine Sciences and Equinox India Developments for favorable stock positions. The Nifty is expected to sustain a positive bi...

1 year ago - The Times of India